Avenue Therapeutics (ATXI) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares.
View ATXI analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year target prices for Avenue Therapeutics' shares. Their ATXI share price forecasts range from $32.00 to $32.00. On average, they anticipate the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 4,537.7% from the stock's current price.
View analysts price targets for ATXI or view top-rated stocks among Wall Street analysts.

Avenue Therapeutics' stock was trading at $1.16 at the start of the year. Since then, ATXI shares have decreased by 40.5% and is now trading at $0.69.
View the best growth stocks for 2023 here.

Avenue Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 26,700 shares, an increase of 184.0% from the August 31st total of 9,400 shares. Based on an average daily trading volume, of 70,100 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.5% of the company's shares are sold short.
View Avenue Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ATXI earnings forecast.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.52) EPS for the quarter.

Shares of Avenue Therapeutics reverse split before market open on Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO).

(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATXI stock can currently be purchased for approximately $0.69.

Avenue Therapeutics (NASDAQ:ATXI) has a market capitalization of $5.64 million. The company earns $-3,550,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The official website for the company is www.avenuetx.com. The company can be reached via phone at (781) 652-4500 or via email at ir@avenuetx.com.